August 30, 2019 / 1:24 PM / 2 months ago

Patent court to review Alexion's Soliris patents on Amgen challenge - filings

Aug 30 (Reuters) - The U.S. patent office will review three patents on Alexion Pharmaceuticals Inc’s drug Soliris, after rival Amgen Inc filed a petition challenging them, court filings showed on Friday.

The Patent Trial and Appeal Board, a court run by the U.S. patent office, said it was instituting an inter-party review on the patents.

Soliris is approved for two rare blood disorders, paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, and brought in sales of $980.8 million for Alexion in the quarter ended June 30. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below